UroGen Pharma (URGN) Current Deferred Revenue (2017 - 2018)
UroGen Pharma (URGN) posted quarterly Current Deferred Revenue of $86000.0 for Q2 2018, down 56.12% on a QoQ basis from $196000.0 in Q1 2018.
UroGen Pharma (URGN) Current Deferred Revenue (2017 - 2018) Analysis & Trends
UroGen Pharma (URGN) has reported Current Deferred Revenue for 2 consecutive years, with $86000.0 the latest figure, recorded in Q2 2018.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $86000.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $86000.0 (changed N/A YoY) and the FY2017 annual result came in at $650000.0, changed N/A from the prior year.
- Current Deferred Revenue retreated to $86000.0 in Q2 2018 per URGN's latest filing, from $196000.0 in the prior quarter.
- Over the last five years, Current Deferred Revenue for URGN reached as high as $650000.0 in Q4 2017 and fell as low as $86000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 86,000.00 |
| Mar 31, 2018 | 196,000.00 |
| Dec 31, 2017 | 650,000.00 |